Does Rallies show Form 4 insider transactions for ELUT?

Yes. Rallies tracks ELUT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ELUT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ELUT. It does not provide personalized investment advice.

ELUT (Elutia Inc. Class A Common Stock) Stock Analysis - Insider Trades

Elutia Inc. Class A Common Stock (ELUT) is a publicly traded Healthcare sector company. As of May 21, 2026, ELUT trades at $1.18 with a market cap of $48.63M and a P/E ratio of 0.91. ELUT moved +6.70% today. Year to date, ELUT is +92.18%; over the trailing twelve months it is -35.16%. Its 52-week range spans $0.50 to $5.12. Analyst consensus is buy with an average price target of $5.00. Rallies surfaces ELUT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ELUT stock inside the company?

Recent ELUT insider activity includes RAKIN KEVIN bought 70.00K, NEELS GUIDO J bought 20.00K, NEELS GUIDO J bought 15.00K, NEELS GUIDO J bought 15.00K, and RAKIN KEVIN bought 50.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ELUT Key Metrics

Key financial metrics for ELUT
Metric	Value
Price	$1.18
Market Cap	$48.63M
P/E Ratio	0.91
EPS	$1.29
Dividend Yield	0.00%
52-Week High	$5.12
52-Week Low	$0.50
Volume	0
Avg Volume	0
Revenue (TTM)	$12.29M
Net Income	$53.38M
Gross Margin	53.66%

Recent ELUT Insider Trades

RAKIN KEVIN bought 70.00K (~$74.20K) on Jan 30, 2026.
NEELS GUIDO J bought 20.00K (~$20.80K) on Jan 30, 2026.
NEELS GUIDO J bought 15.00K (~$15.90K) on Jan 29, 2026.
NEELS GUIDO J bought 15.00K (~$15.90K) on Jan 28, 2026.
RAKIN KEVIN bought 50.00K (~$26.00K) on Dec 17, 2025.

Latest ELUT News

Elutia Reports Q1 Sales Growth to $3.1M, Gross Margin Rises to 58%, Net Loss Widens — May 15, 2026
Elutia Seeks FDA Clearance for NXT-41 in H2 2026 with $44.4M Cash — Mar 11, 2026
Elutia Raises 2025 Revenue Estimate to $18.9M, 2026 Forecast Cut — Mar 10, 2026
Elutia names Pete Ligotti as CCO to launch NXT-41x in $1.5B breast surgery market — Mar 2, 2026
Elutia Earns Great Place to Work Certification with 62% Female Leadership — Feb 18, 2026

ELUT Analyst Consensus

1 analysts cover ELUT: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.00.

Common questions about ELUT

Who is trading ELUT stock inside the company?: Recent ELUT insider activity includes RAKIN KEVIN bought 70.00K, NEELS GUIDO J bought 20.00K, NEELS GUIDO J bought 15.00K, NEELS GUIDO J bought 15.00K, and RAKIN KEVIN bought 50.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ELUT?: Yes. Rallies tracks ELUT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ELUT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ELUT. It does not provide personalized investment advice.